PMID- 34126957
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jun 15
TI  - Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in 
      the conversion therapy of unresectable gastric cancer.
PG  - 702
LID - 10.1186/s12885-021-08459-3 [doi]
LID - 702
AB  - BACKGROUND: We conducted a single-arm phase II trial to investigate the 
      short-term efficacy and safety of apatinib combined with oxaliplatin and S-1 in 
      the treatment of unresectable gastric cancer. PATIENTS AND METHODS: Previously 
      untreated patients with unresectable HER-2-negative advanced gastric cancer were 
      selected. All the patients received six cycles of S-1 and oxaliplatin and five 
      cycles of apatinib, which were administered at intervals of three weeks. The 
      surgery was performed after six cycles of drug treatment. The primary endpoints 
      were radical resection (R0) rate and safety. This study was registered with the 
      China Trial Register, number ChiCTR-ONC-17010430  (01/12/2016-01/12/2022). 
      RESULTS: A total of 39 patients were enrolled. Efficacy evaluation was feasible 
      for 37 patients. One patient achieved complete response (CR, 2.7%), 26 patients 
      achieved partial response (PR, 70.3%), three patients had stable disease (SD, 
      8.1%) and seven patients had progressive disease (PD, 18.9%). The objective 
      response rate (ORR) was 73.0% and the disease control rate (DCR) was 81.1%. 22 
      patients underwent surgery, among which 14 patients underwent radical resection 
      (R0), with a R0 resection rate of 63.6%. The 1-year survival rate of the surgical 
      group (22 patients) was 71.1% and the 2-year survival rate was 41.1%. The median 
      survival time was 21 months. The incidence of adverse events (AEs) was 100%. 
      Leucopenia (65.3%) and granulocytopenia (69.2%) were the most common 
      hematological AEs. The most common non-hematological AEs were fatigue (51.3%) and 
      oral mucositis (35.9%). CONCLUSION: Apatinib combined with oxaliplatin and S-1 
      showed good short-term survival and acceptable safety in the conversion therapy 
      of unresectable gastric cancer.
FAU - Ye, Zaisheng
AU  - Ye Z
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
FAU - Zeng, Yi
AU  - Zeng Y
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
FAU - Wei, Shenghong
AU  - Wei S
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
FAU - Lin, Zhitao
AU  - Lin Z
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
FAU - Chen, Shu
AU  - Chen S
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
FAU - Wang, Zhiwei
AU  - Wang Z
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
FAU - Chen, Shanshan
AU  - Chen S
AD  - Department of Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer 
      Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian 
      Province, China.
FAU - Chen, Luchuan
AU  - Chen L
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian 
      Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China. 
      luchuanchen@sina.cn.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20210615
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Drug Combinations)
RN  - 0 (Pyridines)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5S371K6132 (apatinib)
RN  - 5VT6420TIG (Oxonic Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxaliplatin/pharmacology/*therapeutic use
MH  - Oxonic Acid/pharmacology/*therapeutic use
MH  - Pyridines/pharmacology/*therapeutic use
MH  - Stomach Neoplasms/*drug therapy/mortality
MH  - Survival Analysis
MH  - Tegafur/pharmacology/*therapeutic use
PMC - PMC8204414
OTO - NOTNLM
OT  - Apatinib
OT  - Conversion therapy
OT  - Efficacy
OT  - Safety
OT  - Unresectable gastric cancer
COIS- The authors declare that they have no competing interests.
EDAT- 2021/06/16 06:00
MHDA- 2021/11/03 06:00
PMCR- 2021/06/15
CRDT- 2021/06/15 05:48
PHST- 2021/01/13 00:00 [received]
PHST- 2021/06/07 00:00 [accepted]
PHST- 2021/06/15 05:48 [entrez]
PHST- 2021/06/16 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/06/15 00:00 [pmc-release]
AID - 10.1186/s12885-021-08459-3 [pii]
AID - 8459 [pii]
AID - 10.1186/s12885-021-08459-3 [doi]
PST - epublish
SO  - BMC Cancer. 2021 Jun 15;21(1):702. doi: 10.1186/s12885-021-08459-3.